Impact of weight gain on outcomes in type 2 diabetes

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1431-1438

  Ross, Stuart A ^a   Dzida, Grzegorz ^b   Vora, Jiten ^c   Khunti, Kamlesh ^d   Kaiser, Marcel ^e   Ligthelm, Robert J ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e Private Practice   (Germany)

^f EHM Clinic   (Netherlands)

Author keywords

Antidiabetic drugs; Cardiovascular; Morbidity; Mortality; Obesity; Type 2 diabetes; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

DIABETIC PATIENT; DISEASE COURSE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

COMORBIDITY; DIABETES MELLITUS, TYPE 2; HUMANS; MODELS, BIOLOGICAL; OBESITY; OVERWEIGHT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 79958838741     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.585396     Document Type: Review

References (69)

1. Haslam DW, James WPT. Obesity. Lancet 2005;366:1197-209. (Pubitemid 41393598)
2. World Cancer Research Fund, American Institute for Cancer Research (AICR). Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington, DC: AICR, 2007.
3. Burke GL, Bertoni AG, Shea S, et al. The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 2008;168:928-35. (Pubitemid 351679632)
4. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial. Diabetes Care 2007;30:1374-83. (Pubitemid 46871141)
5. Whitlock G, Lewington S, Sherliker P, et al. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.
6. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21-33.
7. Abdullah A, Peeters A, de Courten M, et al. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract 2010;89:309-19.
8. Rodbard HW, Fox KM, Grandy S; for the SHIELD Study Group. Impact of obesity on work productivity and role disability in individuals with and at risk for diabetes mellitus. Am J Health Promot 2009;23:353-60.
9. Goetzel RZ, Gibson TB, Short ME, et al. A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med 2010;52(Suppl 1):S52-8.
10. Sullivan PW, Ghushchyan V, Ben-Joseph RH. The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. Obesity 2008;16:2155-62.
11. Kushner RF, Sujak M. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. Obesity 2009;17:1017-22.
12. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. The Evidence Report. Washington, DC: National Institutes of Health, September 1998.
13. Fujimoto WY, Jablonski KA, Bray GA, et al. Diabetes Prevention Program Research Group. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes 2007;56:1680-5. (Pubitemid 46842603)
14. Knowler WC, Barrett-Connor E, Fowler SE, et al.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
15. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-50. (Pubitemid 32378388)
16. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of noninsulin- dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997;145:614-19. (Pubitemid 27154864)
17. Conen D, Ridker PM, Mora S, et al. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J 2007; 28:2937-43. (Pubitemid 350233022)
18. Balthasar N. Feeding signals to the hungry mind. Exp Physiol 2009; 94:857-66.
19. Allison DB, Downey M, Atkinson RL, et al. TOS Obesity as a Disease Writing Group. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity 2008; 16:1161-77. (Pubitemid 351770522)
20. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
21. Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72.
22. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001;161:1581-6. (Pubitemid 32681139)
23. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105. (Pubitemid 29466221)
24. Yusuf S, Hawken S, Ounpuu S, et al.INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-52. (Pubitemid 39208455)
25. Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health 2005;59:134-9. (Pubitemid 40139326)
26. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9. (Pubitemid 29504045)
27. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9. (Pubitemid 37254901)
28. Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008;31: 1582-4.
29. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. (Pubitemid 351831356)
30. Flegal KM, Graubard BI, Williamson DF, et al. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298: 2028-37. (Pubitemid 350074800)
31. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist 2010; 15:556-65.
32. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
33. Parr CL, Batty GD, Lam TH, et al. Asia-Pacific Cohort Studies Collaboration. Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol 2010;11:741-52.
34. Yki-Jä rvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43. (Pubitemid 27525508)
35. Pani LN, Nathan DM, Grant RW. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%. Diabetes Care 2008;31:386-90.
36. Dale J, Martin S, Gadsby R. Insulin initiation in primary care patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes 2010; 4:85-9.
37. Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960-5.
38. Dixon J, O'Brien P, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. JAMA 2008;299:316-32.
39. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499-504.
40. Lean ME, Powrie JK, Anderson AS, et al. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990;7:228-33. (Pubitemid 20104137)
41. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res 2001;9(Suppl 4):326S-34S.
42. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-87.
43. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150: 803-8.
44. Hollander P. Anti-diabetes and anti-obesity medications: effects on weight in people with diabetes. Diab Spect 2007;20:159-65. (Pubitemid 47492972)
45. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83-8.
46. Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010;303:1410-18.
47. Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007;146:477-85. (Pubitemid 351650556)
48. Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologia 2009; 52:1990-2000.
49. Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736-47.
50. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Tech Assess 2010;14:1-268.
51. Hermansen K, Lund P, Clemmensen K, et al. on behalf of the Danish PREDICTIVE study group. 3-Month results from Denmark within the globally prospective and observational study to evaluate insulin detemir treatment in type 1 and type 2 diabetes: The PREDICTIVE Study. Rev Diabet Stud 2007;4:89-97. (Pubitemid 47451182)
52. Dornhurst A, Luddeke H-J, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study. Int J Clin Pract 2008; 62:4:659-65. (Pubitemid 351348041)
53. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801:311-19.
54. Chavez JA, Summers SA. Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta 2010; 1801:252-65.
55. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-93. (Pubitemid 29056924)
56. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91. (Pubitemid 34655345)
57. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148-52. (Pubitemid 37339512)
58. Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-14. (Pubitemid 44115345)
59. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008;37:603-21.
60. Hamlat N, Forcheron F, Negazzi S, et al. Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulinresistance. Cardiovasc Diabetol 2009;8:64.
61. Gupta AK, Smith SR, Greenway FL, et al. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab 2009;11:330-7.
62. Yang Y, Thumula V, Pace PF, et al. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study. Clin Ther 2009;31:2178-88.
63. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27:2149-53. (Pubitemid 39167177)
64. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;19:279-84. (Pubitemid 34592152)
65. Freeman JS. New therapeutic options: management strategies to optimize glycemic control. J Am Osteopath Assoc 2010;110(3 Suppl 2):S15-20.
66. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-S24. (Pubitemid 35034478)
67. Mosnier-Pudar H, Hochberg G, Eschwege E, et al. How patients' attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS Survey. Diabetes Metab 2010;36(6 Pt 1):476-83.
68. Brod M, Cobden D, Lammert M, et al. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health Qual Life Outcomes 2007;5:8.
69. Hauber AB, Mohamed AF, Johnson FR, et al. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucoselowering agents. Diabet Med 2009;26:416-24